Stock market announcement archive

LIFE – Successfully ISO 13485 certified

January 9, 2024
Bergen, Norway, January 9th, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has received the official documentation for ISO 13485 certification. Reference is made to Lifecare’s stock exchange notification 27th of November 2022 when the ISO 13495 […]
Read more

LIFE: Notofication of trade by party closely related to primary insider

December 15, 2023
Bergen, Norway, December 15th, 2023. Islay Ventures GmbH (“IV”) a company wholly owned and controlled by Lifecare CSO Prof. Dr. Dr. Med Andreas Pfützner, has today reported to have sold 320,800 shares in the Company at an average price of NOK 3.476. The transaction represents 12,24% of IV’s original holding. After the transaction IV owns […]
Read more

LIFE: Final purchase order for automated production components – micro-fluidic handling and dispensing devices

December 13, 2023
Bergen, Norway, December 13th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that yet an additional preparational step for the Company’s automated production has been met as Lifecare has placed the purchase order for a BioScaffolder (“BS 3.3) and a customized Nano-Plotter […]
Read more

LIFE: Purchase order on scanning electron microscope from Zeiss

November 28, 2023
Bergen, Norway, November 28th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a SEM (abbreviation for Scanning Electron Microscope) from the German supplier Carl Zeiss AG. Reference is made to Lifecare’s list of trigger […]
Read more

LIFE: Successful ISO 13485 audit

November 20, 2023
Bergen, Norway, November 20th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has been successfully audited as part of the upcoming ISO 13485 certification. Reference is made to Lifecare’s list of trigger events, as presented at the […]
Read more

LIFE: Lifecare Q3 2023 Report

November 14, 2023
Bergen, Norway, November 14th, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q3 financial report and operational update. Lifecare completed Q3 with many important technology and operational achievements. The Company is shifting focus from conducting research and development to focusing on […]
Read more

LIFE: The European Patent Office intends to issue new Lifecare patent

November 8, 2023
Bergen, Norway, November 8th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has reported its intent to grant Lifecare a new patent. Lifecare will review the examining division’s comments to the patent application and respond to the […]
Read more

LIFE: Lifecare receives regulatory approval to start LFC-SEN-002

November 7, 2023
Bergen, Norway, November 7th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that The Norwegian Food Safety Authority (NFSA) has awarded all necessary approvals to start LFC-SEN-002. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of […]
Read more